PMC-403 / PharmAbcine - LARVOL DELTA

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration (PRNewswire) - "PharmAbcine...announced that its TIE2-activating antibody candidate, PMC-403, has received unanimous safety approval from the Safety Review Committee (SRC) for the 4mg single ascending dose (SAD) cohort in its Phase 1 clinical trial for neovascular age-related macular degeneration (nAMD). The Company is now preparing to begin enrollment for the 4mg multiple ascending dose (MAD) cohort....This Phase 1 trial targets patients with neovascular AMD who no longer respond to anti-VEGF standard therapies. The safety and tolerability of the 4mg single dose were successfully confirmed, laying the groundwork for advancing to the multiple-dosing phase."

DSMB • Trial status • Wet Age-related Macular Degeneration

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg (PRNewswire) - "PharmAbcine...announced today the decision to advance PMC-403, its candidate treatment for neovascular age-related macular degeneration (nAMD), to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in Phase 1 clinical trial....This Phase 1 trial targets patients with neovascular age-related macular degeneration who are no longer responding to anti-VEGF standard therapeutics. With the SRC's decision, the trial will advance to the highest single dose cohort (4mg) and the first multiple ascending dose cohort (3mg), potentially providing more advanced data from this Phase 1 study."

Trial status • Wet Age-related Macular Degeneration

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: PharmAbcine | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CRP

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD (PRNewswire-Asia) - "PharmAbcine...announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration). The study, consisting of single ascending-dose cohort and multiple ascending-dose cohort, has dosed the first of 36 planned study subjects. The Phase I clinical trial, an open-label, multi-center, single and multiple ascending-dose study, is currently enrolling patients at multiple hospitals in South Korea, including Seoul National University Bundang Hospital."

Trial status • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: PharmAbcine

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CRP